Evotec SE (EVOTF) Asset Writedowns and Impairment (2021 - 2023)
Evotec SE's (EVOTF) quarterly Asset Writedowns and Impairment came in at -$5520.6 in Q4 2023, down 42161.44% quarter-over-quarter from -$13.06 in Q3 2023.
Evotec SE (EVOTF) Asset Writedowns and Impairment (2021 - 2023) Analysis & Trends
Evotec SE has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting -$5520.6 for Q4 2023.
- Asset Writedowns and Impairment for Q4 2023 came in at -$5520.6, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was -$11611.2 (changed N/A YoY), and the FY2025 annual result was $927742.7, down 92.88% from the prior year.
- Asset Writedowns and Impairment came in at -$5520.6 for Q4 2023 at Evotec SE, down from -$13.06 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of -$13.06 in Q3 2023 to a low of -$5520.6 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Evotec SE | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -5,520.65 |
| Dec 31, 2023 | -5,520.65 |
| Sep 30, 2023 | -13.06 |
| Sep 30, 2023 | -13.06 |
| Dec 31, 2021 | -781.33 |
| Dec 31, 2021 | -781.33 |
| Sep 30, 2021 | -5,296.18 |
| Sep 30, 2021 | -5,296.18 |
| Jun 30, 2021 | -822.52 |
| Jun 30, 2021 | -822.52 |